Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUN PHARMA Mar-20 |
MYLAN Dec-18 |
SUN PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 484 | 3,554 | - | |
Low | Rs | 315 | 1,956 | - | |
Sales per share (Unadj.) | Rs | 136.9 | 1,635.5 | - | |
Earnings per share (Unadj.) | Rs | 17.5 | 44.4 | - | |
Cash flow per share (Unadj.) | Rs | 26.0 | 350.6 | - | |
Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
Dividend yield (eoy) | % | 1.0 | 0 | - | |
Book value per share (Unadj.) | Rs | 188.7 | 1,769.3 | - | |
Shares outstanding (eoy) | m | 2,399.26 | 514.50 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.9 | 1.7 | 173.3% | |
Avg P/E ratio | x | 22.9 | 62.0 | 36.9% | |
P/CF ratio (eoy) | x | 15.4 | 7.9 | 195.6% | |
Price / Book Value ratio | x | 2.1 | 1.6 | 136.0% | |
Dividend payout | % | 22.9 | 0 | - | |
Avg Mkt Cap | Rs m | 958,864 | 1,417,614 | 67.6% | |
No. of employees | `000 | 17.8 | 35.0 | 50.7% | |
Total wages/salary | Rs m | 63,624 | 0 | - | |
Avg. sales/employee | Rs Th | 18,490.6 | 24,041.6 | 76.9% | |
Avg. wages/employee | Rs Th | 3,582.6 | 0 | - | |
Avg. net profit/employee | Rs Th | 2,357.6 | 652.8 | 361.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 328,375 | 841,456 | 39.0% | |
Other income | Rs m | 6,360 | 0 | - | |
Total revenues | Rs m | 334,735 | 841,456 | 39.8% | |
Gross profit | Rs m | 69,898 | 217,738 | 32.1% | |
Depreciation | Rs m | 20,528 | 157,554 | 13.0% | |
Interest | Rs m | 3,027 | 40,471 | 7.5% | |
Profit before tax | Rs m | 52,702 | 19,713 | 267.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -2,606 | 0 | - | |
Tax | Rs m | 8,228 | -3,136 | -262.4% | |
Profit after tax | Rs m | 41,868 | 22,849 | 183.2% | |
Gross profit margin | % | 21.3 | 25.9 | 82.3% | |
Effective tax rate | % | 15.6 | -15.9 | -98.1% | |
Net profit margin | % | 12.8 | 2.7 | 469.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 316,542 | 469,868 | 67.4% | |
Current liabilities | Rs m | 157,064 | 342,586 | 45.8% | |
Net working cap to sales | % | 48.6 | 15.1 | 321.1% | |
Current ratio | x | 2.0 | 1.4 | 146.9% | |
Inventory Days | Days | 88 | 84 | 104.7% | |
Debtors Days | Days | 105 | 93 | 112.2% | |
Net fixed assets | Rs m | 243,102 | 163,229 | 148.9% | |
Share capital | Rs m | 2,399 | 448 | 535.5% | |
Net worth | Rs m | 452,645 | 910,302 | 49.7% | |
Long term debt | Rs m | 20,289 | 982,508 | 2.1% | |
Total assets | Rs m | 682,525 | 2,441,784 | 28.0% | |
Interest coverage | x | 18.4 | 1.5 | 1,237.9% | |
Debt to equity ratio | x | 0 | 1.1 | 4.2% | |
Sales to assets ratio | x | 0.5 | 0.3 | 139.6% | |
Return on assets | % | 6.6 | 2.6 | 253.7% | |
Return on equity | % | 9.2 | 2.5 | 368.5% | |
Return on capital | % | 11.2 | 3.2 | 353.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 65,548 | 174,855 | 37.5% | |
From Investments | Rs m | -25,888 | -90,381 | 28.6% | |
From Financial Activity | Rs m | -57,151 | -81,458 | 70.2% | |
Net Cashflow | Rs m | -13,857 | 1,449 | -956.6% |
Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare SUN PHARMA With: J.B.CHEMICALS ELDER PHARMA AUROBINDO PHARMA GSK PHARMA NATCO PHARMA
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
More Views on NewsIn this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More